Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

943
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
943
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

62
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
62
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

273
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
273
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

50
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
50
Lipid Absorption01:24

Lipid Absorption

1.1K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zinc deficiency and sarcopenia define a metabolic frailty phenotype predicting hepatic encephalopathy and early mortality in cirrhosis.

Metabolic brain disease·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement.

Clinical kidney journal·2026
Same author

Gender Differences in Major Risk Factors for Cardiovascular Disease in Mexican Adults.

Global heart·2026
Same author

Insulin resistance and metabolic health predict cardiorespiratory fitness: cohort study.

European heart journal open·2026
Same author

Editorial: Lipidology at the Dawn of a New Era.

Diabetes, metabolic syndrome and obesity : targets and therapy·2025

Related Experiment Video

Updated: Oct 10, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

New Therapies for Primary Hyperlipidemia.

Carlos A Aguilar-Salinas1,2, Rita A Gómez-Díaz3, Pablo Corral4

  • 1Direction of Nutrition Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

The Journal of Clinical Endocrinology and Metabolism
|December 10, 2021
PubMed
Summary

New therapies for primary hyperlipidemia offer improved treatment options. These novel medications target specific metabolic pathways, potentially increasing treatment success and providing safer alternatives for patients.

Keywords:
familial chylomicronemiafamilial combined hyperlipidemiafamilial hypercholesterolemiahydroxymethylglutaryl-CoA reductase inhibitorslipoprotein lipase activators

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Related Experiment Videos

Last Updated: Oct 10, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.6K

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Pharmacology

Background:

  • Primary hyperlipidemias are genetic disorders causing high cholesterol or triglycerides, leading to severe health risks.
  • Many primary hyperlipidemia cases remain undiagnosed or undertreated, highlighting a gap in patient care.
  • Existing treatments like statins, ezetimibe, and fibrates are effective but may not be suitable for all patients.

Purpose of the Study:

  • To provide an updated overview of current and emerging therapies for primary hyperlipidemia.
  • To discuss the mechanisms and potential clinical applications of newly approved lipid-lowering drugs.
  • To evaluate how novel treatments can complement existing therapies and improve patient outcomes.

Main Methods:

  • Review of recently FDA and EMA-approved lipid-lowering medications.
  • Analysis of drugs targeting novel metabolic pathways: (adenosine 5'-triphosphates)-citrate lyase, proprotein convertase subtilisin/kexin 9, apolipoprotein CIII, and angiopoietin-like 3.
  • Discussion of the additive effects and potential clinical indications of these new agents.

Main Results:

  • Several new drugs targeting key lipid metabolism pathways have received regulatory approval.
  • These novel medications demonstrate additive effects when used with established therapies.
  • Potential for improved achievement of lipid treatment targets and safer alternatives for patients experiencing side effects.

Conclusions:

  • The introduction of new medications expands therapeutic options for primary hyperlipidemia.
  • These advancements may enhance treatment efficacy and patient adherence.
  • Novel therapies offer a promising outlook for managing complex lipid disorders and reducing cardiovascular risk.